Longitudinal measurement of anticardiolipin antibodies during normal pregnancy: a prospective study

Abstract

We have previously shown that elevation of anticardiolipin antibodies (aCL) at the first prenatal visit is associated with increased fetal loss in normal pregnancy. The variation in aCL levels during normal pregnancy has not been established. To examine this question we measured IgG, IgM and IgA aCL levels five times during pregnancy at weeks 5-15, 16-25, 26-35, 36-37 and at delivery. Data were analyzed to determine: (a) the within and between subject variability of aCL during pregnancy; (2) the temporal trend of aCL; and (3) the relation of serial measures of aCL with maternal complications of pregnancy.

We divided our cohort of 354 subjects into two groups. Group A included those subjects with consistently normal levels of aCL and group B those subjects with at least one elevated level of aCL. In group A the within subject variability was relatively low (28-34%). In group B we found wide fluctuations in aCL levels and a within subject variability of 88-91 %. Subjects in group B had no increase in maternal complications of pregnancy.

The present data suggest that aCL may fluctuate significantly during normal pregnancy and there is little clinical value in measuring aCL on a serial basis during pregnancy.

Keywords

anticardiolipin antibodies antiphospholipid antibodies pregnancy serial study complications of pregnancy

Get full access to this article

View all access options for this article.

References

Khamashta MA et al. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 1995; 332: 993-997.

Hughes GR The antiphospholipid syndrome: ten years on. Lancet 1993; 342: 341-344.

Lockshin MD Antiphospholipid antibody syndrome. Rheum Dis Clin North Am 1994; 20: 45-59.

Vianna JL et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 1994; 96: 3-9.

Shoenfeld Y. Induction of experimental primary and secondary antiphospholipid syndromes in naive mice. Am J Reprod Immunol 1992; 28: 219-221.

Branch DW et al. 'Immunoglobulin G fractions' from patients with antiphospholipid antibodies cause fetal death in Balb/c mice: a model for automine fetal loss . Am J Obstet Gynecol 1990; 163: 210-216.

Lockshin MD Lupus and antiphospholipid antibody syndrome: either, neither or both . Am J Med 1994; 96: 1-2.

Triplett DA Antiphospholipid antibodies: proposed mechanisms of action. Am J Reprod Immunol 1992; 28: 211-215.

Rote NS , Walter A. , Lyden TW Antiphospholipid antibodies: lobsters or red herrings? Am J Reprod Immunol 1992; 28: 31-37.

10.

Isenberg DA et al. The relationship of anti-DNA antibody idiotypes and anticardiolipin antibodies to disease activity in systemic lupus erythematosus. Medicine 1986; 65: 46-55.

11.

Kalunian KC et al. Clinical significance of a single test for anticardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med 1988; 85: 602-607.

12.

Ishii Y. et al. Clinical importance of persistence of anticardiolipin antibodies in systemic lupus erythematosus. Ann Rheum Dis 1990; 49: 387-390.

13.

Ginsberg JS et al. Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: a cross-sectional study. Blood 1992; 80: 975-980.

14.

Out HJ et al. Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis 1989; 48: 1023-1028.

15.

Derksen Rhwm et al. Discordant effects of prednisone on anticardiolipin antibodies and the lupus anticoagulant. Arthritis Rheum 1986; 29: 1295-1296.

16.

Lubbe WF et al. Fetal survival after prednisone suppression of maternal lupus-anticoagulant . Lancet 1983; 1: 1361-1363.

17.

Hedfors E. , Lindahl G. , Lindblad S. Anticardiolipin antibodies during pregnancy. J Rheumatol 1987; 14: 160-161.

18.

Keane A. et al. A serial study of anticardiolipin antibody and antimitochondrial antibody type M5 in a patient with polyarthritis and polymyositis. Br J Rheumatol 1989; 28: 158-160.

19.

Fort JG et al. Anticardiolipin antibodies in patients with rheumatic diseases . Arthritis Rheum 1987; 30: 752-760.

20.

Lynch A. et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. Ann Intern Med 1994; 120: 470-475.

21.

Lockwood CJ et al. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol 1989; 161: 369-373.

22.

Perez MC et al. Anticardiolipin antibodies in unselected pregnant women. Relationship to fetal outcome. J Perinat 1991; 11: 33-36.

23.

Harris EN , Spinnato JA

Should anticardiolipin tests be performed in otherwise healthy pregnant women?

Am J Obstet Gynecol 1991; 165: 1272-1277.

24.

Pattison NS et al. Antiphospholipid antibodies in pregnancy: prevalence and clinical associations. Br J Obstet Gynecol 1993; 100: 909-913.

25.

Gabbe SG , Niebyl JR , Simpson JL (eds). Obstetrics: Normal Problem Pregnancies. Churchill Livingstone: New York, 1986.

26.

Laird NM , Ware JH Random effects models for longitudinal data. Biometrics 1982; 38: 963-974.

27.

Sturfelt G. et al. Anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1987; 30: 382-388.

28.

Peaceman AM , Silver RK , MacGregor SN Interlaboratory variation in antiphospholipid antibody testing. Am J Obstet Gynecol 1992 ; 166: 1780-1784.

29.

Out HJ et al. Prevalence of antiphospholipid antibodies in patients with fetal loss. Ann Rheum Dis 1991; 50: 553-557.

30.

Drenkard C. , Sánchez-Guerrero J. , Alarcón-Segovia D. Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus. J Rheumato l 1989; 16: 614-617.

31.

Buchanan Nmm et al. A study of 100 high risk lupus pregnancies . Am J Reprod Immunol 1992; 28: 192-194.

32.

Asherson RA et al. Antiphospholipid syndrome: five year follow-up. Ann Rheum Dis 1991; 50: 805-810.

33.

Polzin WJ et al. The association of antiphospholipid antibodies with pregnancies complicated by fetal growth restriction. Obstet Gynecol 1991; 78: 1108-1111.

34.

Branch DW et al. The association of antiphospholipid antibodies with severe pre-eclampsia . Obstet Gynecol 1989; 73: 541-545.

35.

Viscarello RR et al. Prevalence and prognostic significance of anticardiolipin antibodies in pregnancies complicated by human immunodeficiency virus-1 infection. Am J Obstet Gynecol 1992 ; 167: 1080-1085.